Chemicals

lawsone

We are lawsone CAS:83-72-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:lawsone

CAS.NO:83-72-7

Synonyms:1,4-Naphthalenedione, 2-hydroxy-

2-Hydroxy-p-naphthoquinone

2-Hydroxy-1,4-naphoquinone;

Molecular Formula:C10H6O3

Molecular Weight:174.15300

Physical and Chemical Properties:

Density:1.46;

Melting point:192-195oC;

Boiling point:339.908oC;

Specification:

Appearance:Light yellow crystal

Purity(HPLC):≥99.0%

Ash:≤0.5%

Loss on drying:≤0.5%

Fe content:≤100ppm

Packing:25 kg/drum, can also be packaged according to customer requirements

Storage:Store in a cool, ventilated place

Application:Hair dyes intermediate

lawsone

Related News: The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.5-Bromo-2-ethoxypyridine CAS:55849-30-4 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.40161-54-4 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.4286-55-9 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Product Name
2′-Hydroxy-4′-methylacetophenone Cas:6921-64-8	View Details
Trimethylsilylmethyl Acetate Cas:2917-65-9	View Details
2,4-Difluorobenzyl Bromide Cas:23915-07-3	View Details